Iantrek Announces $42 Million Series C Funding to Launch Breakthrough Glaucoma Therapy AlloFlo™ Uveo
Iantrek, Inc., a pioneer in bio-interventional ophthalmic surgery, today announced the closing of a $42 million Series C financing round. This investment will accelerate the U.S. commercial launch of AlloFlo™ Uveo, the first interventional glaucoma therapy targeting the uveoscleral pathway,…